James F. Howard Jr., MD

July 25, 2022

James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, deliver parting thoughts on the state of the myasthenia gravis treatment, focusing on current deficits and future prospects.

July 25, 2022

Two subject matter experts discuss promising treatment methods and agents in the pipeline for patients with myasthenia gravis.

July 18, 2022

James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN, discuss the efficacy and safety of FcRn inhibitors, as well as consider their role in the rapidly evolving treatment landscape.

July 18, 2022

Experts discuss the benefits of complement inhibitors in reducing symptoms of myasthenia gravis.

July 11, 2022

James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, review the role of complement inhibitors and FcRn inhibitors in the management of myasthenia gravis.

July 11, 2022

Thought leaders review the role of non-pharmacological strategies to manage myasthenia gravis comorbidities.

July 06, 2022

A comprehensive review of drugs to avoid when designing treatment plans for patients with myasthenia gravis.

July 06, 2022

Experts recommend approaches for special cases including ocular myasthenia gravis, pregnant patients and children with myasthenia gravis, and more.

June 27, 2022

Recommendations from neurologists James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN for addressing acute exacerbation in patients with myasthenia gravis.

June 27, 2022

Two subject matter experts discuss cases where a thymectomy is appropriate for treating patients with myasthenia gravis.